Table 2

Results of rhodamine 123 efflux assays for 18 compounds selected from National Cancer Institute Drug Screen Repository

Mean channel shift of rhodamine fluorescence in SW620 Ad300 cells2-a
1 μM10 μM100 μM
NSC number (class)2-b
  38270 (S)44380
 328426 (S)00283
 339281 (S)025 2-c
 359449 (S)029128
 630176 (S)363235
 633043 (S)000
 640085 (S)111819
 666490 (S)000
  68075 (A)55326331
 665333 (A)165391357
 667739 (A)362360362
 676590 (A)48163419
 676591 (A)144348420
 676597 (A)219438447
 676599 (A)0188452
 676600 (A)186205307
 676605 (O)51281304
 668360 (O)N.D.192415
Vinblastine079516
Doxorubicin0029
Paclitaxel189284291
Colchicine1130
CsA202381373
PSC 833330362401
Verapamil75316407
  • 2-a Difference in rhodamine fluorescence intensity in the presence and absence of 1, 10, and 100 μm of the tested drug (mean channel shift). 0, Absence of detectable effect.

  • 2-b Classification determined by assays in Tables1 and 2: S, substrate; A, antagonist; and O, compounds in overlap group.

  • 2-c Autofluorescence is too high at 100 μm to be reliable.

  • N.D., not determined.